Neuromedin U-25 (human) 

Neuromedin U-25 human is the active form of neuromedin U in human. Neuromedin U-25 human inhibits glucose-stimulated insulin secretion, which leads to early-onset obesity. Neuromedin U-25 serves as vasoconstrictor in human vascular beds^[1][2].

Neuromedin U-25 human (4 pM-2 nM) binds to receptors in human left ventricle and coronary artery with K_Ds of 0.26 and 0.11 nM, respectively^[1].
Neuromedin U-25 human (0.1 nM-0.1 μM) constricts coronary artery, mammary artery and saphenous vein endothelium-independently, with potency pD₂s of 8.6, 8.0 and 8.2, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

3080.37

C₁₄₁H₂₀₃N₄₁O₃₈

312306-89-1

Phe-Arg-Val-Asp-Glu-Glu-Phe-Gln-Ser-Pro-Phe-Ala-Ser-Gln-Ser-Arg-Gly-Tyr-Phe-Leu-Phe-Arg-Pro-Arg-Asn-NH2

FRVDEEFQSPFASQSRGYFLFRPRN-NH2

C([C@@H](NC([C@H](CC1=CC=CC=C1)NC([C@@H](NC([C@H](CC2=CC=CC=C2)NC([C@H](CC3=CC=C(O)C=C3)NC(CNC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(=O)[C@H]4N(C([C@@H](NC([C@@H](NC([C@H](CC5=CC=CC=C5)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](CC6=CC=CC=C6)N)=O)CCCNC(=N)N)=O)C(C)C)=O)CC(O)=O)=O)CCC(O)=O)=O)CCC(O)=O)=O)=O)CCC(N)=O)=O)CO)=O)CCC4)CC7=CC=CC=C7)=O)C)=O)CO)=O)CCC(N)=O)=O)CO)=O)CCCNC(=N)N)=O)=O)=O)=O)CC(C)C)=O)=O)CCCNC(=N)N)(=O)N8[C@H](C(N[C@H](C(N[C@@H](CC(N)=O)C(N)=O)=O)CCCNC(=N)N)=O)CCC8

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Mitchell JD, et al., Expression and vasoconstrictor function of anorexigenic peptides neuromedin U-25 and S in the human cardiovascular system. Cardiovasc Res. 2009 Feb 1;81(2):353-61.  [Content Brief]

  [2]. Alfa RW, et al., Suppression of insulin production and secretion by a decretin hormone. Cell Metab. 2015 Feb 3;21(2):323-334.  [Content Brief]